Zobrazeno 1 - 10
of 132
pro vyhledávání: '"Dalia Ricci"'
Autor:
Alessandro Di Federico, Valentina Tateo, Claudia Parisi, Francesca Formica, Riccardo Carloni, Giorgio Frega, Alessandro Rizzo, Dalia Ricci, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi
Publikováno v:
Pharmaceuticals, Vol 14, Iss 7, p 677 (2021)
Pancreatic cancer (PC) is a recalcitrant disease characterized by high incidence and poor prognosis. The extremely complex genomic landscape of PC has a deep influence on cultivating a tumor microenvironment, resulting in the promotion of tumor growt
Externí odkaz:
https://doaj.org/article/aafb77fec1f64a0385c302ab2b577ecd
Autor:
Carmelo Laface, Angela Dalia Ricci, Simona Vallarelli, Carmela Ostuni, Alessandro Rizzo, Francesca Ambrogio, Matteo Centonze, Annalisa Schirizzi, Giampiero De Leonardis, Rosalba D’Alessandro, Claudio Lotesoriere, Gianluigi Giannelli
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 14, p 7737 (2024)
Autotaxin (ATX) is a member of the ectonucleotide pyrophosphate/phosphodiesterase (ENPP) family; it is encoded by the ENPP2 gene. ATX is a secreted glycoprotein and catalyzes the hydrolysis of lysophosphatidylcholine to lysophosphatidic acid (LPA). L
Externí odkaz:
https://doaj.org/article/74487963409a485b99101e393a73cc42
Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
Autor:
Alessandro Rizzo, Angela Dalia Ricci, Antonio Cusmai, Silvana Acquafredda, Giuseppe De Palma, Giovanni Brandi, Gennaro Palmiotti
Publikováno v:
Current Oncology, Vol 29, Iss 2, Pp 551-564 (2022)
Recent years have seen some breakthroughs in the therapeutic landscape of advanced biliary tract cancer (BTC). Firstly, a better understanding of the molecular background of BTC has led to important improvements in the management of these hepatobilia
Externí odkaz:
https://doaj.org/article/4a27d1ea4b4a4df0a1bf3d8ba5993a70
Autor:
Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, Raffaele De Luca, Deniz Can Guven, Suayib Yalcin, Giovanni Brandi
Publikováno v:
Translational Oncology, Vol 25, Iss , Pp 101514- (2022)
Systemic treatments (e.g., chemotherapy and targeted therapies) have limited efficacy for patients with locally advanced – unresectable – and metastatic cholangiocarcinoma (CCA), with an overall survival of less than a year. Tumor microenvironmen
Externí odkaz:
https://doaj.org/article/5100a02873d64aa1bc6cba5336784642
Autor:
Giovanni Brandi, Angela Dalia Ricci, Alessandro Rizzo, Chiara Zanfi, Simona Tavolari, Andrea Palloni, Stefania De Lorenzo, Matteo Ravaioli, Matteo Cescon
Publikováno v:
Cancer Communications, Vol 40, Iss 9, Pp 461-464 (2020)
Externí odkaz:
https://doaj.org/article/72020fc41be84fd2b6da044ae17221fb
Autor:
Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, Giorgio Frega, Andrea Palloni, Simona Tavolari, Giovanni Brandi
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy worldwide, still representing an important cause of cancer-related death. Over the next few years, novel systemic treatment options have emerged. Among these, immune
Externí odkaz:
https://doaj.org/article/e8a448411e034eae9038f398e3b1f9ce
Autor:
Andrea Palloni, Silvia Bisello, Ilaria Maggio, Maria Massucci, Andrea Galuppi, Alessandro Di Federico, Alessandro Rizzo, Angela Dalia Ricci, Giambattista Siepe, Alessio Giuseppe Morganti, Giovanni Brandi, Giorgio Frega
Publikováno v:
Current Oncology; Volume 30; Issue 5; Pages: 4754-4766
(1) Background: Biliary tract cancers (BTCs) are a heterogeneous group of neoplasms with dismal prognosis and the role of adjuvant chemoradiotherapy in high-risk resected patients is unclear. (2) Methods: We retrospectively analyzed the outcomes of B
Autor:
Angela Dalia Ricci, Rosalba D'Alessandro, Alessandro Rizzo, Annalisa Schirizzi, Simona Vallarelli, Carmela Ostuni, Laura Troiani, Ivan Roberto Lolli, Claudio Lotesoriere, Gianluigi Giannelli
Publikováno v:
Immunotherapy. 15:477-486
Following the practice-changing results observed in several hematological and solid tumors, immunotherapy with immune checkpoint inhibitors (ICIs) has been tested in cholangiocarcinoma (CCA) patients. However, ICI monotherapy has had disappointing re
Publikováno v:
Liver Cancer, Pp 1-2 (2021)
Externí odkaz:
https://doaj.org/article/be18db7380934f9e9d3f5ee9e0bf0b8f
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss , Pp 100337- (2021)
Cholangiocarcinoma (CCA) includes a heterogeneous group of malignancies with limited treatment options. Despite recent advances in medical oncology, the prognosis of CCA patients with metastatic disease remains poor, with a median overall survival of
Externí odkaz:
https://doaj.org/article/698dc883b2144460aae7de053fee0c0c